Medimetriks Highlights

- Specialty pharma company targeting medical Dermatology
  - Established commercial operations with a Sales Force approaching 40 strong in key US markets
    - Marketed brands for treatment of acne, rosacea, atopic dermatitis, fungal infections and nail dystrophy
  - Integrated clinical drug development capabilities
    - Development team has broad experience working with FDA and achieving NDA approvals, including Xepi™ (ozenoxacin cream), December 2017

- Development pipeline: MM36 (Difamilast)
  - Novel topical, non-steroidal PDE4 inhibitor for atopic dermatitis and itch
    - Demonstrated safety, efficacy and rapid itch relief in Phase 2 clinical trials
    - Preparing for Phase 3 trials
Business Overview

1. Strong Existing Portfolio & Commercial Platform
   - Existing portfolio of positive cash flow dermatology brands sold through national US sales force
   - Commercial expertise in maximizing brand value in key medical dermatology markets
   - Acquiring commercialized assets to leverage company infrastructure and commercial platform

2. Development Expertise & Lifecycle Management
   - Line extension development provides growth potential prior to MM36 launch
   - Achieved FDA approval of Xepi™ (ozenoxacin) cream, a topical antibiotic for impetigo Dec. 2017

3. MM36: Blockbuster Brand Launch
   - Potential best in class treatment in the large, underserved US AD market
   - Over 18MM US patients affected and >14MM prescriptions written for mild-to-moderate AD
   - MM36 Phase 2 studies demonstrate strong competitive profile:
     - Fast and sustained itch relief
     - Stronger efficacy profile
     - Safe, well-tolerated and minimally absorbed
Commercial Expertise

- **Expanding National Field Force in medical Dermatology**
  - Sales force approaching 40 strong in the highest potential markets
  - Wide breadth and depth across Dermatology and Podiatry

- **Commercial experts in creating, launching and maximizing brands**
  - Senior Management has long-standing and strong relationships with Key Opinion Leaders and High Volume Prescribers

- **Core brand Growth Drivers**

<table>
<thead>
<tr>
<th>Acne &amp; Rosacea</th>
<th>Skin &amp; Scalp Dermatoses</th>
<th>Inflammatory Skin Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clindacin* (clindamycin phosphate)</td>
<td>Clodan* (clobetasol propionate)</td>
<td>Genadur* (hydrosoluble nail lacquer)</td>
</tr>
<tr>
<td>Neuac* (clindamycin/benzoyl peroxide)</td>
<td>Neo-Synalar* (fluocinolone acetonide/neomycin)</td>
<td>Neo-Synalar* (fluocinolone acetonide)</td>
</tr>
<tr>
<td>Sumadan* (sodium sulfacetamide/sulfur)</td>
<td>Synalar* (fluocinolone acetonide)</td>
<td>Nicadan* (niacinamide)</td>
</tr>
</tbody>
</table>
Atopic Dermatitis Portfolio

**Synalar® Brand Franchise**

- Synalar® has tremendous equity in Dermatology and is the foundation of Medimetriks’ expertise in the atopic dermatitis (AD) market
  - **Brands:** Synalar® Cream, Ointment, Topical Solution & Neo-Synalar® Cream
  - **Lead brand:** Neo-Synalar®
    - The only dual active steroid-antibiotic available for the treatment of steroid-responsive dermatoses with secondary infection
      - *S. aureus* is present in >90% of adult patients with AD
      - Potential first-line therapy for acute AD when infection is a concern
      - Marketing exclusivity based on clinical/regulatory activities for dual-active formulation development, required clinical trials and ANDA approval timing
MM36: Blockbuster Pipeline Asset

• Novel topical, non-steroidal PDE4 inhibitor for atopic dermatitis (AD) and itch
  – Phase 2 studies demonstrated rapid improvement of itch and objective signs of AD
    ▪ Median time to itch improvement of 5.8 hours vs. Eucrisa® at 32.9 hours¹
    ▪ Subjects with moderate or severe disease achieved a 60% median reduction in itch by hour 4
  – AD improvement in both EASI and IGA
    ▪ Clinically superior results vs. vehicle and tacrolimus 1% (Protopic®)
    ▪ Safe, well-tolerated (minimal application site reaction) and minimally absorbed

• MM36 has potential to be a disruptive treatment in large, under-served AD and itch markets
• Preparing for Phase 3 trials
• Patent protection through 2033

¹ Hebert, Eichenfeld, Lebwohl et al. Poster presented at Fall Clinical Dermatology Conference October 1-4, 2015, Las Vegas, NV
Note: Not head-to-head studies
MM36: Mild-to-Moderate AD Market Opportunity

**Market Overview**

- 18MM+ US patients affected by mild-to-moderate eczema with 14MM+ TRx written in the US
  - Safety is important as disease presents by age 5 in ~85% of cases
- Pfizer acquired Anacor Pharmaceuticals, developers of Eucrisa®, in June 2016 for US$5.2 billion
  - Estimated peak US sales for Eucrisa® are >$1.5B*

**Unique Opportunity**

- Atopic Dermatitis treated by a highly concentrated prescriber base in Dermatology, Pediatrics and select PCPs
- MM36 offers distinct advantages versus Eucrisa® and Protopic® based on MM36 early itch, efficacy and safety data

MM36 has potential to be the best-in-class atopic dermatitis treatment

---

* Goldman Sachs Group, November 3, 2015
** Symphony Health weekly TRx annualized and multiplied by current WAC, June 1, 2018